Open AccessThe clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer
Author(s) -
Turkan Ozturk Topcu,
Feyyaz Özdemir,
Halil Kavgacı,
Meral Günaldı,
Hakan Koçoğlu,
Gökşen İnanç Imamoğlu,
Ahmet Menteşe,
Serap Özer Yaman,
Asım Örem,
Faruk Aydin
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.174547
Subject(s) - urokinase receptor , anthracycline , supar , chemotherapy , breast cancer , medicine , metastasis , epirubicin , oncology , cancer , urokinase , gastroenterology
Breast cancer mortality rates after metastasis is high. Urokinase plasminogen activator receptor (uPAR) and carbonic anhydrase IX (CAIX) play very important roles during tumor cell invasion and metastasis. The purpose of this study was to evaluate plasma levels of uPAR and CAIX and the effect of anthracycline-based chemotherapy on these biomarkers in patients with operable breast cancer.